Results of Clinical Trials with the Administration of Interleukin 2 and Adoptive Immunotherapy with Activated Cells in Patients with Cancer

This publication has 31 references indexed in Scilit:

• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
  The Journal of Experimental Medicine, 1985
• Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer
  Cancer, 1985
• Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli
  Science, 1984
• Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells
  Cancer, 1984
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
  The Journal of Experimental Medicine, 1984
• Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.
  The Journal of Experimental Medicine, 1983
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982
• Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line.
  The Journal of Experimental Medicine, 1980
• Identification of T cell lymphoma tumor antigens on human T cell lines
  American Journal of Hematology, 1976